BeiGene Ltd. ADR (BGNE) News

BeiGene Ltd. ADR (BGNE): $249.12

3.94 (+1.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BGNE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter BGNE News Items

BGNE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BGNE News Highlights

  • BGNE's 30 day story count now stands at 36.
  • Over the past 21 days, the trend for BGNE's stories per day has been choppy and unclear. It has oscillated between 1 and 14.
  • DRUG, DECK and INTU are the most mentioned tickers in articles about BGNE.

Latest BGNE News From Around the Web

Below are the latest news stories about BEIGENE LTD that investors may wish to consider to help them evaluate BGNE as an investment opportunity.

Quebec becomes first province to cover PrBRUKINSA® (zanubrutinib) for the Treatment of Waldenström's macroglobulinemia

BeiGene Canada, the affiliate of BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that the Government of Quebec will publicly fund BRUKINSA® (zanubrutinib), a second generation inhibitor of Bruton's tyrosine kinase (BTK), for the treatment of adult patients with Waldenström's macroglobulinemia (WM), a rare blood cancer. As of February 1st, 2023, BRUKINSA will be included on the List of Medications reimbursed under the Régie de l'assurance

Yahoo | February 6, 2023

New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., February 03, 2023--BeiGene has released a report highlighting the challenges cancer patients and caregivers face in managing mental and emotional well-being.

Yahoo | February 3, 2023

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 40% Undervaluation?

Today we will run through one way of estimating the intrinsic value of BeiGene, Ltd. ( NASDAQ:BGNE ) by taking the...

Yahoo | February 3, 2023

BeiGene to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, February 01, 2023--BeiGene announced that the Company will participate in two upcoming investor conferences.

Yahoo | February 1, 2023

BeiGene: Watch FDA Approval And Valuations

BeiGene''s BRUKINSA has recently obtained approval from the FDA for the treatment of SLL and CLL. See why I rate BGNE stock as a buy.

Seeking Alpha | January 25, 2023

Draganfly To Rally Around 87%? Here Are 10 Other Analyst Forecasts For Friday

SVB Leerink raised the price target for BeiGene, Ltd. (NASDAQ: BGNE ) from $236 to $300. SVB Leerink analyst Andrew Berens maintained an Outperform rating. BeiGene shares rose 2% to $279.90 in pre-market trading. Raymond James cut the price target for Wintrust Financial Corporation (NASDAQ: WTFC ) from $118 to $110. Raymond James analyst David Long maintained a Strong Buy rating. Wintrust Financial shares gained 2.4% to close at $84.77 on Thursday. Keybanc cut the price target for Bill.com Holdings, Inc. (NASDAQ: BILL ) from $175 to $125. Keybanc analyst Josh Beck maintained an Overweight rating on the stock. Bill.com shares fell 3.7% to close at $99.72 on Thursday. Keybanc raised the price target for Intuit Inc. (NASDAQ: INTU ) from $425 to … Full story available on Benzinga.com

Benzinga | January 20, 2023

FDA Approves BeiGene''s Brukinsa For Chronic Lymphocytic Leukemia

The FDA has approved BeiGene Ltd''s (NASDAQ: BGNE ) Bruton''s tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). "With four US approvals in just over three years and demonstrated superiority versus ibrutinib in the final progression-free … Full story available on Benzinga.com

Benzinga | January 20, 2023

BeiGene (BGNE) Presents At 41st Annual Healthcare Conference - Slideshow (NASDAQ:BGNE)

The following slide deck was published by BeiGene, Ltd.

Seeking Alpha | January 20, 2023

Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival

Jazz (JAZZ) reports data from a mid-stage study on its investigational bispecific antibody targeting HER2-expressing mGEA. The treatment achieved an overall survival rate of 84% in 18 months.

Yahoo | January 20, 2023

FDA Approves BeiGene's Brukinsa For Chronic Lymphocytic Leukemia

The FDA has approved BeiGene Ltd's (NASDAQ: BGNE) Bruton's tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). "With four US approvals in just over three years and demonstrated superiority versus ibrutinib in the final progression-free survival (PFS) analysis of the ALPINE trial, we believe BRUKINSA is well-positioned to become the BTKi of choice across multiple indications," said Mehrdad Mobasher, Chief Medical Off

Yahoo | January 20, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5479 seconds.